Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
References: TripleHormoneReceptor Agonist Retatrutide for Obesity A Phase 2 Trial, Jastreboff et al., 2023 NEJM, Retatrutide, a GIP, GLP1 and glucagon receptor agonist, for people with type 2 diabetes, Rosenstock et al., 2023 The Lancet, Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis, Giblin et al., 2025 Diabetes, Obesity and Metabolism, Retatrutide is currently an investigational compound undergoing clinical research and has not yet been approved as a medicine by regulatory authorities.Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country
Hot flashes
It takes 30 seconds
Retatrutide is an investigational injectable medicine being developed primarily for the treatment of obesity and type 2 diabetes
US$ 29.40
US$ 29.46
US$ 29.34
US$ 24.01
